STALICLA products
STALICLA - Robust Pipeline
STALICLA is advancing a robust pipeline of both proprietary and partnered therapeutic packages.
STALICLA - Drug Development Unit
DDU validates ASD phenotype groups and drug candidates through observational studies and investigational trials. DDU combines expertise in operations, medicine, drug and clinical development, to bring STALICLA’s clinical-stage treatment options closer to patients.
STALICLA - Databased Endophenotyping Patient Identification (DEPI) Technology
STALICLA’s precision medicine approach begins with ‘endophenotyping’-identifying the nonbehavioral physical and molecular presentations of NDDs and characterizing subgroups of patients with similar disease signatures. DEPI matches these patient subgroups with an NDD-targeted drug (or drug combination) by integrating and analyzing large omics data sets, including genomics, proteomics, pharmacogenomics and clinical data.
STALICLA - Discovery and Data Science Unit
DDS applies AI-driven and systems biology precision medicine approaches to patient data sets. Bringing together computational biologists, human geneticists, data scientists, chemo-informaticians and developers, DDS ensures that STALICLA’s first-in-class DEPI technology is producing next-generation therapeutics for NDDs.